Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…Abstract Number: 2163 • ACR Convergence 2022
Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and organ involvement and chronic disease course. Systemic inflammation, involvement of the gastrointestinal tract, and glucocorticoid treatment…Abstract Number: 2165 • ACR Convergence 2022
Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
Background/Purpose: Spirometry, in particular forced vital capacity (FVC), is a widely implemented tool in the initial diagnostic workup and monitoring of systemic sclerosis-related interstitial lung…Abstract Number: 2150 • ACR Convergence 2022
Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study
Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…Abstract Number: 2156 • ACR Convergence 2022
Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with microangiopathy and fibrosis affecting the skin and visceral organs. Interstitial lung disease (ILD) is a…Abstract Number: 2162 • ACR Convergence 2022
Systemic Sclerosis in Alaska Native/American Indian People in Alaska
Background/Purpose: Systemic sclerosis (SSc) is known to have more severe manifestations and higher mortality in Black populations, while fewer studies have examined disparities in epidemiology…Abstract Number: 2158 • ACR Convergence 2022
A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort
Background/Purpose: Combined Care in Systemic Sclerosis (CCISS) is a prospective cohort of patients referred to Leiden University Medical Center for Raynaud's Phenomenon (RP), a suspicion…Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…Abstract Number: 2107 • ACR Convergence 2022
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
Background/Purpose: Advances in medicine for women with systemic lupus erythematosus (SLE) have led to improved pregnancy outcomes, but pregnancies are still high-risk and disparities remain.…Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…Abstract Number: 1783 • ACR Convergence 2022
Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
Background/Purpose: Physical activity (PA) is effective in the self-management of arthritis. As such, several evidence-based programs aimed at supporting safe and meaningful PA have been…Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
- « Previous Page
- 1
- …
- 476
- 477
- 478
- 479
- 480
- …
- 2425
- Next Page »